|European Case Law Identifier:||ECLI:EP:BA:2022:T059122.20220923|
|Date of decision:||23 September 2022|
|Case number:||T 0591/22|
|IPC class:||A61K 31/135
|Language of proceedings:||EN|
|Download and more information:||
|Title of application:||RAPID DISSOLUTION FORMULATION OF A CINACALCET HCL|
|Applicant name:||Amgen Inc.|
|Opponent name:||Teva Pharmaceutical Industries Ltd
Gillard, Richard Edward
Glenmark Pharmaceuticals Europe Ltd
MAIWALD PATENTANWALTS- UND
betapharm Arzneimittel GmbH
|Relevant legal provisions:||
|Keywords:||Admissibility of appeal - missing statement of grounds|
Summary of Facts and Submissions
I. The appeal is directed against the decision of the opposition division posted on 16 December 2021.
II. The appellant filed a notice of appeal on 28 February 2022 and paid the appeal fee on the same day.
III. By communication of 18 May 2022, receipt of which was confirmed by the appellant, the Registry of the Board informed the appellant that it appeared from the file that the written statement of grounds of appeal had not been filed, and that it was therefore to be expected that the appeal would be rejected as inadmissible pursuant to Article 108 EPC, third sentence in conjunction with Rule 101(1) EPC. The appellant was informed that any observations had to be filed within two months of notification of the communication.
IV. No reply was received.
Reasons for the Decision
No written statement of grounds of appeal was filed within the time limit provided by Article 108, third sentence, EPC in conjunction with Rule 126(2) EPC. In addition, neither the notice of appeal nor any other document filed contains anything that could be regarded as a statement of grounds pursuant to Article 108 EPC and Rule 99(2) EPC. Therefore, the appeal has to be rejected as inadmissible (Rule 101(1) EPC).
For these reasons it is decided that:
The appeal is rejected as inadmissible.